{"id":32850,"date":"2025-05-06T14:42:41","date_gmt":"2025-05-06T06:42:41","guid":{"rendered":"https:\/\/flcube.com\/?p=32850"},"modified":"2025-05-06T14:42:42","modified_gmt":"2025-05-06T06:42:42","slug":"eli-lilly-reports-45-yoy-sales-growth-in-q1-2025-driven-by-mounjaro-and-zepbound","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32850","title":{"rendered":"Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound"},"content":{"rendered":"\n<p>US-based Eli Lilly &amp; Co. (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) released its Q1 2025 financial report, revealing sales growth of 45% year-on-year (YOY) in constant currency terms to USD 12.73 billion. This growth was driven by a 53% increase in volume, partially offset by a 6% decrease due to lower realized prices and a 2% unfavorable impact of foreign exchange rates. Core product revenues stood at USD 7.52 billion after a 119% expansion, driven by Zepbound and Mounjaro. Net profit rose 23% YOY to USD 2.73 billion, representing 21.5% of total revenue, reflecting continued investment in early- and late-stage R&amp;D pipelines.<\/p>\n\n\n\n<p><strong>US Revenue Performance<\/strong><br>Revenue in the US increased 49% to USD 8.49 billion, with 46% volume growth led by Mounjaro and, to a lesser extent, Jardiance. The Jardiance growth included a USD 370 million one-time gain from an amended collaboration agreement with Boehringer Ingelheim, which adjusted commercialization responsibilities in select markets.<\/p>\n\n\n\n<p><strong>Mounjaro Revenue<\/strong><br>During Q1, worldwide Mounjaro revenue increased 113% to USD 3.84 billion. US revenue was USD 2.66 billion, an increase of 75%, reflecting continued strong demand, partially offset by lower realized prices. Revenue outside the US increased to USD 1.19 billion compared with USD 286.2 million in Q1 2024, primarily driven by volume growth, including entry into new markets, partially offset by lower realized prices.<\/p>\n\n\n\n<p><strong>Zepbound and Verzenio Revenue<\/strong><br>For Q1 2025, US Zepbound revenue was USD 2.31 billion, compared with USD 517.4 million in Q1 2024, primarily driven by increased demand, partially offset by lower realized prices. For Q1 2025, worldwide Verzenio revenue increased 10% to USD 1.16 billion. US revenue was USD 657.6 million, an increase of 3%, driven by higher realized prices. Increased demand was more than offset by wholesaler buying patterns and competitive dynamics. Revenue outside the US was USD 501.3 million, an increase of 22%, primarily driven by volume growth, partially offset by the unfavorable impact of foreign exchange rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US-based Eli Lilly &amp; Co. (NYSE: LLY) released its Q1 2025 financial report, revealing sales&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32852,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[199,27,911],"class_list":["post-32850","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-eli-lilly","tag-finanical-reports","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Eli Lilly &amp; Co. (NYSE: LLY) released its Q1 2025 financial report, revealing sales growth of 45% year-on-year (YOY) in constant currency terms to USD 12.73 billion. This growth was driven by a 53% increase in volume, partially offset by a 6% decrease due to lower realized prices and a 2% unfavorable impact of foreign exchange rates. Core product revenues stood at USD 7.52 billion after a 119% expansion, driven by Zepbound and Mounjaro. Net profit rose 23% YOY to USD 2.73 billion, representing 21.5% of total revenue, reflecting continued investment in early- and late-stage R&amp;D pipelines.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32850\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound\" \/>\n<meta property=\"og:description\" content=\"US-based Eli Lilly &amp; Co. (NYSE: LLY) released its Q1 2025 financial report, revealing sales growth of 45% year-on-year (YOY) in constant currency terms to USD 12.73 billion. This growth was driven by a 53% increase in volume, partially offset by a 6% decrease due to lower realized prices and a 2% unfavorable impact of foreign exchange rates. Core product revenues stood at USD 7.52 billion after a 119% expansion, driven by Zepbound and Mounjaro. Net profit rose 23% YOY to USD 2.73 billion, representing 21.5% of total revenue, reflecting continued investment in early- and late-stage R&amp;D pipelines.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32850\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-06T06:42:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-06T06:42:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0503.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"607\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32850#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32850\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound\",\"datePublished\":\"2025-05-06T06:42:41+00:00\",\"dateModified\":\"2025-05-06T06:42:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32850\"},\"wordCount\":301,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32850#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0503.webp\",\"keywords\":[\"Eli Lilly\",\"Finanical Reports\",\"NYSE: LLY\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32850#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32850\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32850\",\"name\":\"Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32850#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32850#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0503.webp\",\"datePublished\":\"2025-05-06T06:42:41+00:00\",\"dateModified\":\"2025-05-06T06:42:42+00:00\",\"description\":\"US-based Eli Lilly & Co. (NYSE: LLY) released its Q1 2025 financial report, revealing sales growth of 45% year-on-year (YOY) in constant currency terms to USD 12.73 billion. This growth was driven by a 53% increase in volume, partially offset by a 6% decrease due to lower realized prices and a 2% unfavorable impact of foreign exchange rates. Core product revenues stood at USD 7.52 billion after a 119% expansion, driven by Zepbound and Mounjaro. Net profit rose 23% YOY to USD 2.73 billion, representing 21.5% of total revenue, reflecting continued investment in early- and late-stage R&D pipelines.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32850#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32850\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32850#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0503.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0503.webp\",\"width\":1080,\"height\":607,\"caption\":\"Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32850#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound - Insight, China&#039;s Pharmaceutical Industry","description":"US-based Eli Lilly & Co. (NYSE: LLY) released its Q1 2025 financial report, revealing sales growth of 45% year-on-year (YOY) in constant currency terms to USD 12.73 billion. This growth was driven by a 53% increase in volume, partially offset by a 6% decrease due to lower realized prices and a 2% unfavorable impact of foreign exchange rates. Core product revenues stood at USD 7.52 billion after a 119% expansion, driven by Zepbound and Mounjaro. Net profit rose 23% YOY to USD 2.73 billion, representing 21.5% of total revenue, reflecting continued investment in early- and late-stage R&D pipelines.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32850","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound","og_description":"US-based Eli Lilly & Co. (NYSE: LLY) released its Q1 2025 financial report, revealing sales growth of 45% year-on-year (YOY) in constant currency terms to USD 12.73 billion. This growth was driven by a 53% increase in volume, partially offset by a 6% decrease due to lower realized prices and a 2% unfavorable impact of foreign exchange rates. Core product revenues stood at USD 7.52 billion after a 119% expansion, driven by Zepbound and Mounjaro. Net profit rose 23% YOY to USD 2.73 billion, representing 21.5% of total revenue, reflecting continued investment in early- and late-stage R&D pipelines.","og_url":"https:\/\/flcube.com\/?p=32850","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-06T06:42:41+00:00","article_modified_time":"2025-05-06T06:42:42+00:00","og_image":[{"width":1080,"height":607,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0503.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32850#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32850"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound","datePublished":"2025-05-06T06:42:41+00:00","dateModified":"2025-05-06T06:42:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32850"},"wordCount":301,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32850#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0503.webp","keywords":["Eli Lilly","Finanical Reports","NYSE: LLY"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32850#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32850","url":"https:\/\/flcube.com\/?p=32850","name":"Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32850#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32850#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0503.webp","datePublished":"2025-05-06T06:42:41+00:00","dateModified":"2025-05-06T06:42:42+00:00","description":"US-based Eli Lilly & Co. (NYSE: LLY) released its Q1 2025 financial report, revealing sales growth of 45% year-on-year (YOY) in constant currency terms to USD 12.73 billion. This growth was driven by a 53% increase in volume, partially offset by a 6% decrease due to lower realized prices and a 2% unfavorable impact of foreign exchange rates. Core product revenues stood at USD 7.52 billion after a 119% expansion, driven by Zepbound and Mounjaro. Net profit rose 23% YOY to USD 2.73 billion, representing 21.5% of total revenue, reflecting continued investment in early- and late-stage R&D pipelines.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32850#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32850"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32850#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0503.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0503.webp","width":1080,"height":607,"caption":"Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32850#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0503.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32850"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32850\/revisions"}],"predecessor-version":[{"id":32853,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32850\/revisions\/32853"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32852"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}